Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARD-489
- Development stage
- Preclinical
- Lead developer
- Artivila Therapeutics
- Modality
- Small Molecules
01
Overview
ARD-489 (also known as Sunrise) is a small molecule drug candidate developed by Artivila Therapeutics. It is currently being investigated for the treatment of neurodegenerative and neurological conditions, specifically Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Amyotrophic Lateral Sclerosis (ALS). While the drug is a key part of Artivila's pipeline focusing on neurodegeneration, its specific molecular target and mechanism of action have not been publicly disclosed. The candidate is part of a broader portfolio of small molecules and biologics aimed at addressing unmet needs in autoimmune and neurodegenerative diseases.
Beyond the preview
Go deeper on ARD-489.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARD-489.